All In Biotech

Drug Trial Radar · NCT00002368

The Safety and Effectiveness of Nevirapine Plus Lamivudine Plus Other Anti-HIV Drugs

An International, Double Blind, Randomized, Phase III Study to Evaluate the Tolerance, Safety, and Effectiveness of Viramune (Nevirapine) in Preventing Clinical AIDS Progression Events or Death When Used in Combination With Lamivudine (3TC) and Stable (>= 4 Weeks) Background Nucleoside Therapy

Last checked: Nov 19, 2026Latest source record: Jun 24, 2005 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,000

Actual

Start

Not stated

Primary completion

Not stated

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Aug 31, 2001

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Model
Parallel
Primary purpose
Treatment
Who can join
All sexes, from 13 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the tolerance, safety, and effectiveness of Viramune in preventing clinical AIDS progression events or death when used in combination with Lamivudine and background nucleoside therapy.

Conditions

  • HIV Infections

Interventions

  • NevirapineDrug

  • LamivudineDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

53 sites in 1 country. Site status is shown where the registry gives one.

  • Drug Research and Analysis Corp

    Montgomery, Alabama

  • Dr G Michael Wool

    Los Angeles, California

  • UCLA School of Medicine / Ctr for Research and Education

    Los Angeles, California

  • AIDS Research Ctr / Palo Alto VA Health Care System

    Palo Alto, California

  • AIDS Community Research Consortium

    Redwood City, California

  • ViRx Inc

    San Francisco, California

  • San Francisco Gen Hosp / UCSF AIDS Program

    San Francisco, California

  • Harbor - UCLA Med Ctr

    Torrance, California

  • Infectious Disease Specialists

    Colorado Springs, Colorado

  • Denver Public Health

    Denver, Colorado

  • Dr Miguel Mogyoros / Clinical Research Dept

    Denver, Colorado

  • Wilmington Hosp

    Wilmington, Delaware

  • Novum Inc

    Washington D.C., District of Columbia

  • Anthony LaMarca

    Fort Lauderdale, Florida

  • North Broward Hosp District

    Fort Lauderdale, Florida

  • Dr Robert Schwartz

    Fort Myers, Florida

  • McGregor Clinic / Lee County Public Health Unit

    Fort Myers, Florida

  • P Andrew Coley

    Jacksonville, Florida

  • Goodgame Med Group

    Maitland, Florida

  • Infectious Disease Research Institute Inc

    Tampa, Florida

  • Palm Beach Research Ctr

    West Palm Beach, Florida

  • Dr John Pottage

    Chicago, Illinois

  • Northwestern Univ / Division of Infectious Diseases

    Chicago, Illinois

  • Rush Presbyterian / Saint Luke's Med Ctr / Infect Dis

    Chicago, Illinois

  • Indiana Univ Med School

    Indianapolis, Indiana

  • Dr Daniel H Gervich

    Des Moines, Iowa

  • Univ of Iowa

    Iowa City, Iowa

  • Univ of Kentucky Med Cntr / Dept of Med / Div of ID

    Lexington, Kentucky

  • Med Research Ctr

    New Orleans, Louisiana

  • New England Med Ctr

    Boston, Massachusetts

  • Beth Israel Hosp / Virology Research Clinic

    Boston, Massachusetts

  • New England Deaconess Hosp

    Boston, Massachusetts

  • International Medicine and Infectious Disease

    Minneapolis, Minnesota

  • Trinity Lutheran Hosp / HIV Program

    Kansas City, Missouri

  • Infectious Disease Associates of Central New Jersey

    Somerville, New Jersey

  • SUNY / Erie County Med Ctr at Buffalo

    Buffalo, New York

  • Dr David Kaufman

    New York, New York

  • Saint Vincent Med Ctr

    Staten Island, New York

  • Associates in Med and Mental Health

    Tulsa, Oklahoma

  • The Research and Education Group

    Portland, Oregon

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.